ReviewHepatobiliary surgery and nutrition2015
Fatty liver disease in diabetes mellitus.
Review in Hepatobiliary surgery and nutrition, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 4 syntheses or guidelines pooled it, 200 citations in OpenAlex.
- Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury.BMC complementary medicine and therapies · 2025Pooled it
- Prevalence of nonalcoholic fatty liver disease in Pakistan: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2023Pooled it
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study.Journal of diabetes and its complications · 2023Trial
- Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes.Clinical and molecular hepatology · 2019Trial
- Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study.British journal of clinical pharmacology · 2018Trial
- Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease.Clinical and molecular hepatology · 2018Trial
- Trial
- Integrated apoptotic extracellular vesicle-recruitment peptide coating reprograms the diabetic bone microenvironment and orchestrates enhanced implant osseointegration.Bioactive materials · 2026Article
- Tumour Necrosis Factor-α Promotes Pyroptosis in Diabetic Liver Injury via the HMGB1/TLR4/MyD88/NF-κB Pathway.Journal of cellular and molecular medicine · 2026Article
- SORBS2: A Molecular Nexus in Multisystem Diseases Through Scaffold-Mediated Regulation.Journal of cellular and molecular medicine · 2026Review
- Vibration-controlled transient elastography in pediatric metabolic dysfunction-associated steatotic liver disease.Journal of pediatric gastroenterology and nutrition · 2026Article
- Association of the Fibrosis-4 Index With Indices of Atherosclerosis in Patients With Type 2 Diabetes: An Exploratory Subanalysis of a Prospective Observational Cohort Study.Journal of diabetes research · 2026Observational
- Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes.World journal of hepatology · 2025Review
- The first link between ADAMTS-13 and apoptosis in type 1 diabetic liver injury.Histochemistry and cell biology · 2025Article
- Impact of Antihypertensive and Lipid-Lowering Agents on Hepatocellular Carcinoma Risk in Patients with Fatty Liver Disease and Diabetes.Digestive diseases and sciences · 2025Article
- Effects of Weight Loss on Insulin Resistance and Liver Health in T2DM and NAFLD Patients.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Article
- Enhanced fatty acid oxidation in osteoprogenitor cells provides protection from high-fat diet induced bone dysfunction.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in type 2 diabetes mellitus (T2DM), likely reflecting the frequent occurrence of obesity and insulin resistance in T2DM. NAFLD also can occur in type 1 DM (T1DM), but must be distinguished from the more common glycogen hepatopathy as a cause of hepatomegaly and liver function abnormalities in T1DM. Weight reduction achieved by diet and exercise is effective in preventing and treating NAFLD in obese diabetic subjects. Bariatric surgery also has been shown to reverse NAFLD in T2DM, and recently approved weight loss medications should be evaluated for their impact on the development and progression of NAFLD. There is limited evidence suggesting that specific drugs used for blood glucose control in T2DM [thiazolidinediones (TZDs), glucagon-like peptide-1 (GLP-1) analogs, and dipeptidyl peptidase-4 (DPP-4) inhibitors] and also statins may have a role in preventing or treating NAFLD in patients with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.